Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice

被引:70
作者
Oki, T
Takagi, Y
Inagaki, S
Taketo, MM
Manabe, T
Matsui, M
Yamada, S
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Biopharmaceut Sci, Shizuoka 4228526, Japan
[2] Univ Shizuoka, Sch Pharmaceut Sci, COE Program 21st Century, Shizuoka 4228526, Japan
[3] Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Neuronal Network, Tokyo, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto, Japan
来源
MOLECULAR BRAIN RESEARCH | 2005年 / 133卷 / 01期
关键词
muscarinic acetylcholine receptor subtype; knockout mice; CNS distribution;
D O I
10.1016/j.molbrainres.2004.09.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have studied binding parameters (K-d, B-max)0 Of [H-3]N-methylscopolamine ([H-3]NMS) in various brain regions and spinal cord of wildtype (WT) and muscarinic acetylcholine receptor (mAChR) subtype M-1-M-5 knockout (KO) mice. In the M-1-M-4 KO mice, the number of [3H]NMS binding sites was decreased throughout the central nervous system (CNS) with significant regional differences. Our results collectively suggest that M-1 receptor was present in a relatively high density in the cerebral cortex and hippocampus, and the densities of M I and M-4 subtypes were highest in the corpus striatum. M-2 receptor appeared to be the major subtype in the thalamus, hypothalamus, midbrain, pons-medulla, cerebellum and spinal cord. These findings may contribute significantly not only to the further understanding of the physiological roles of mAChR subtypes in the central cholinergic functions, but also to the development of selective therapeutic agents targeting specific subtype. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 35 条
[1]  
BERNARD V, 1992, J NEUROSCI, V12, P3591
[2]  
BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646
[3]   Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system [J].
Bymaster, FP ;
McKinzie, DL ;
Felder, CC ;
Wess, J .
NEUROCHEMICAL RESEARCH, 2003, 28 (3-4) :437-442
[4]  
DORJE F, 1991, MOL PHARMACOL, V40, P459
[5]   Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice [J].
Duttaroy, A ;
Gomeza, J ;
Gan, JW ;
Siddiqui, N ;
Basile, AS ;
Harman, WD ;
Smith, PL ;
Felder, CC ;
Levey, AI ;
Wess, J .
MOLECULAR PHARMACOLOGY, 2002, 62 (05) :1084-1093
[6]  
EHLERT FJ, 1989, J PHARMACOL EXP THER, V251, P660
[7]  
EHLERT FJ, 1990, J PHARMACOL EXP THER, V255, P1148
[8]   REGIONAL STUDIES OF CATECHOLAMINES IN RAT BRAIN .I. DISPOSITION OF [3H]NOREPINEPHRINE [3H]DOPAMINE AND [3H]DOPA IN VARIOUS REGIONS OF BRAIN [J].
GLOWINSKI, J ;
IVERSEN, LL .
JOURNAL OF NEUROCHEMISTRY, 1966, 13 (08) :655-+
[9]   Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice [J].
Gomeza, J ;
Shannon, H ;
Kostenis, E ;
Felder, C ;
Zhang, L ;
Brodkin, J ;
Grinberg, A ;
Sheng, H ;
Wess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (04) :1692-1697
[10]   Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice [J].
Gomeza, J ;
Zhang, L ;
Kostenis, E ;
Felder, C ;
Bymaster, F ;
Brodkin, J ;
Shannon, H ;
Xia, B ;
Deng, CX ;
Wess, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (18) :10483-10488